Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Enzalutamide in Castration-resistant Prostate Cancer

A comparison with bicalutamide

Publish date:: February 2, 2016

Enzalutamide significantly reduced risk of prostate cancer progression or death compared with bicalutamide in patients with nonmetastatic or metastatic castration-resistant prostate cancer (CRPC). This according to a study of 396 men with nonmetastatic (n=139) or metastatic (n=257) CRPC. Researchers found:

Enzalutamide reduced risk of progression or death by 76% vs bicalutamide.

Median progression-free survival (PFS) was 19.4 months with enzalutamide vs 5.7 months with bicalutamide.

Enzalutamide resulted in significant improvements in all key secondary endpoints: time to PSA progression (HR=0.19), proportion of patients with a ≥ 50% PSA response (81% vs 31%), and radiographic PFS in metastatic patients (HR=0.32).

Beneficial effects with enzalutamide were seen in both metastatic and nonmetastatic subgroups.

The adverse event profile of enzalutamide was consistent with previous trials.

Citation: Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. [Published online ahead of print January 25, 2016]. J Clin Oncol. doi:10.1200/JCO.2015.64.9285.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,